文献速递腹部CT

结直肠癌肝转移MDCT上的强化环:预测无进展生存期和贝伐珠单抗化疗反应的能力评估

Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
PubMed 文献 · AJR Am J Roentgenol · 2020-09-29

该研究回顾性纳入两家机构2012至2018年111例不可切除结直肠癌肝转移患者,评估治疗前门静脉期MDCT强化环对1年无进展生存期和贝伐珠单抗化疗客观缓解率的预测价值。结果显示强化环是1年无进展生存期(HR 0.510)和客观缓解率(OR 4.694)的独立预测因子。

要点

  • 门静脉期MDCT强化环是结直肠癌肝转移患者贝伐珠单抗化疗1年无进展生存期的独立预测因子(HR 0.510)。
  • 强化环也是客观缓解率的独立预测因子(OR 4.694)。
  • 肝切除手术史与1年无进展生存期显著相关(卡方检验,p=0.005)。

诊断标准与关键数值

  • 门静脉期强化环预测1年无进展生存期:风险比0.510(95%CI 0.282-0.926;p=0.027)。
  • 门静脉期强化环预测客观缓解率:比值比4.694(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this article is to evaluate the enhanced rim on the portal venous phase (PVP) on MDCT as a predictor of 1-year progression-free survival (PFS) and response to bevacizumab-based chemotherapy in patients with colorectal liver metastases (CRLM). MATERIALS AND METHODS. We retrospectively identified 111 patients with primary unresectable CRLM treated with bevacizumab-based chemotherapy at two institutions between 2012 and 2018. Pretreatment contrast-enhanced MDCT images were reviewed and data on clinical characteristics were collected from the electronic medical records. Univariable and multivariable analyses were conducted to assess several imaging features and clinical characteristics as potential predictors of 1-year PFS and objective response rate (ORR). RESULTS. After 1 year of follow-up, liver metastatic tumor progression was detected in 52 patients (46.8%) after bevacizumab-based chemotherapy. A log-rank test showed that enhanced rim on PVP (chi-square test, 5.862; p = 0.015) and the occurrence of liver resection surgery (chi-square test, 7.836; p = 0.005) were significant predictors of 1-year PFS. Multivariable analysis showed that enhanced rim on PVP images was an independent predictor of 1-year PFS (hazard ratio, 0.510; 95% CI, 0.282-0.926; p = 0.027) and ORR (odds ratio, 4.694; p < 0.001). CONCLUSION. The presence of an enhanced rim on PVP MDCT is an independent predictor of survival and response to bevacizumab-based chemotherapy among patients with CRLM.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Cheng J, Qiu M, Zhang Y, et al. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy. AJR Am J Roentgenol. 2020. PMID: 32991216. doi:10.2214/AJR.19.22280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。